With open enrollment underway, Illinois' insurance agency is in the midst of establishing a state-based health insurance ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

AbbVie is a leader in the pharmaceutical ... a double-digit dividend growth rate for several years. The credit and debit card issuer is attracting Millennials and Gen Z consumers.

Blue chip stocks are among the safest and most secure buys that investors can add to their portfolios. Here are some of the ...

Other companies: Hess, AbbVie, Kraft Heinz, GE Healthcare and Biogen are all ... September labour market figures and October ...

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on schizophrenia asset emraclidine missed the primary endpoint. AbbVie ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Fees, sign-up bonuses and whether the card is aligned with a particular hotel brand or airline are all factors in the ...

Neuroscience is a key area of focus for AbbVie. In addition to emraclidine, through the Cerevel acquisition AbbVie gained a neuroscience pipeline of multiple clinical-stage and preclinical ...

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

However, much to their credit, Seeking Alpha analysts were mostly positive - and they were right: Data by YCharts The total return since the announcement date is nearly 300%, and AbbVie has been a ...